Navigation Links
Aflac Incorporated Announces Fourth Quarter Results
Date:1/30/2008

COLUMBUS, Ga., Jan. 30 /PRNewswire-FirstCall/ -- Aflac Incorporated (NYSE: AFL) today reported its fourth quarter results.

Total revenues benefited from the strengthening of the yen to the dollar in the fourth quarter, rising 9.0% to $4.0 billion, compared with $3.7 billion in the fourth quarter of 2006. Net earnings were $382 million, or $.78 per diluted share, compared with $332 million, or $.67 per share, a year ago. Net earnings included realized investment losses of $1 million, or nil per diluted share, compared with a gain of $3 million, or $.01 per diluted share in the fourth quarter of 2006. The change in fair value of the interest rate component of the cross-currency swaps related to the company's senior notes, as required by SFAS 133, increased net earnings by $1 million, or nil per diluted share, in the fourth quarter of 2007. The impact from SFAS 133 in the fourth quarter of 2006 was immaterial to net earnings and net earnings per diluted share.

We believe that an analysis of operating earnings, a non-GAAP financial measure, is vitally important to an understanding of Aflac's underlying profitability drivers. We define operating earnings as the profits we derive from our operations before realized investment gains and losses, the impact from SFAS 133, and nonrecurring items. Management uses operating earnings to evaluate the financial performance of Aflac's insurance operations because realized gains and losses, the impact from SFAS 133, and nonrecurring items tend to be driven by general economic conditions and events, and therefore may obscure the underlying fundamentals and trends in Aflac's insurance operations.

Furthermore, because a significant portion of our business is in Japan, where our functional
'/>"/>

SOURCE Aflac Incorporated
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Aflac Incorporated to Accelerate Share Repurchase in 2008; Authorizes Additional Share Repurchase and Increases Quarterly Cash Dividend 17.1%
2. Aflac to Sponsor Iron Girl
3. Aflac Incorporated to Present at the Goldman Sachs Financial Services CEO Conference 2007
4. Aflac Japan To Offer Cancer Insurance Product Through Japan Post
5. Aflac Honors Hispanic Entrepreneurs Making a Difference in Texas
6. Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend
7. Aflac Incorporated to Release Third Quarter Results On October 23, 2007
8. Aflac Announces Resignation of U.S. Marketing Officer
9. Susan G. Komen for the Cures Circle of Promise and The Links, Incorporated Unite to Rewrite the Story on African Americans and Breast Cancer
10. Accuray Incorporated to Report Second Quarter Fiscal Year 2008 Financial Results
11. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... , , CHICAGO, Nov. 30 Phy...oston) reported today on results of a study demons...ronary CT angiography (cCTA) by Rcadia,s COR Analy...oronary artery stenosis in hospital emergency depa... of the automated system to enhance the use of cCT...
(Date:11/30/2009)... , CHICAGONovember 30, 2009A pet owner knows the ...e, especially in troubled times. Most pets are con...aceable companions. A growing body of research now...hild development, elderly care, mental illness, ph...very, and the rehabilitation of incarcerated youth...
(Date:11/30/2009)... , Those extra helpings of gravy and dessert at t...aistline than previously thought. According to a n...e FASEB Journal ( http://www.fasebj.org ), a die...es on genes that ultimately cause our bodies to st...ith a double-whammy as the already difficult task ...
(Date:11/30/2009)... Like a pothole that worsens over time, so do kne... MONDAY, Nov. 30 (HealthDay News) -- If you,re a m...ketball court or hockey rink, take note: A new stu...boost the risk of internal knee damage that could ...the injuries occurred in middle-age people who sho...
(Date:11/30/2009)... , , ENGLEWOOD, Colo., Nov. 30 /PRNe...sional presentation discussing what "culture of sa...Midday Symposium presentation, "Creating a Cultur...lth-system professionals discussing their experien... a culture of safety in pharmacy and the role of t...
Breaking Medicine News(10 mins):Health News:Rcadia COR Analyzer(R) System Demonstrates Potential in Emergency Department Triage of Chest Pain Patients at Low to Moderate Risk of Coronary Artery Disease 2Health News:Rcadia COR Analyzer(R) System Demonstrates Potential in Emergency Department Triage of Chest Pain Patients at Low to Moderate Risk of Coronary Artery Disease 3Health News:The therapeutic benefits of the human-animal bond 2Health News:Western diets turn on fat genes 2Health News:Lots of Exercise in Midlife May Lead to Osteoarthritis 2Health News:Lots of Exercise in Midlife May Lead to Osteoarthritis 3Health News:Baxa to Sponsor ASHP Midday Symposium: Creating a Culture of Safety in Pharmacy, A Panel Discussion on Lessons Learned 2Health News:Baxa to Sponsor ASHP Midday Symposium: Creating a Culture of Safety in Pharmacy, A Panel Discussion on Lessons Learned 3
...ate a new antibiotic, deadly bacteria can counter ... That,s why bacterial infection is the number one ...el Aviv University may give drug developers the up...em, which forces it to reduce its population throu...
...h dental disease among pre-schoolers on the rise, ...g dental professionals in a national campaign to e...rom low-income families. , , On Feb. 6, during th...than 1,600 sites. St. Louis Cardinal first baseman...
..., Retirees and Covered Spouses Invited to Particip...th, LLC., an innovator in employer wellness progra...omprehensive disease prevention and health promoti... participate in the incentive based wellness progr...
...Thrombectomy Device Market to Approach $900 Millio... issued Jan. 7 by Millennium Research Group over P... headline should read "Thrombectomy Device Market ...d to approach $300 million by 2013." rather than "...
...nt Allows Consumers to Cherry Pick Their Antioxida... perfect Valentine,s Day toast, the 7UP brand is r...ry 7UP Antioxidant. The pink-hued, crisp and refr...com.com/cgi-bin/prnh/20080507/LAW016LOGO ) , , "C...
...tients with leg pain caused by arterial disease ma...ry by participating in hospital-supervised exercis...ary issue of Radiology . , Intermittent claudic... endovascular revascularization, a minimally invas...
Other Medicine News:Health News:Can cannibalism fight infections? 2Health News:Can cannibalism fight infections? 3Health News:ADA 'Give Kids A Smile' Events Provide Dental Care to Children from Low-Income Families 2Health News:EngagementHealth(R) Launches Comprehensive Wellness Program with the City of East Moline, Illinois 2Health News:Thrombectomy Device Market to Approach $300 Million by 2013, According to Millennium Research Group 2Health News:Thrombectomy Device Market to Approach $300 Million by 2013, According to Millennium Research Group 3Health News:7UP Gives Consumers a New Reason to Fall in Love - New Cherry 7UP Antioxidant 2
(Date:11/30/2009)...wire/ -- StemCyte, Inc. concluded an exclusive lic... Sinica, the National Laboratory of Taiwan, for ce...y (IP) related to the treatment of Chronic Stroke ... by a team led by Professor John Lin, MD, PhD and ...ently the exclusive collaborator with StemCyte on ...
(Date:11/30/2009)... eHealthSource.com launched the fir...roducts approved for Flexible Spending Account or ... is also the first to exclusively carry value-bran...p to 75 percent on everyday healthcare needs. ,... headaches - high costs and complexity," says eHea...
(Date:11/30/2009)... Health Robotics today announced,it...nd product specifications,for a new and revolution...on", a new key component of its i.v. Room of the F...ooth # 114). , "I look forward to see the...lueprints and to find out if TPNstation appears to...
Breaking Medicine Technology:StemCyte Licenses Promising IP for Stem Cell Therapy to Treat Stroke 2StemCyte Licenses Promising IP for Stem Cell Therapy to Treat Stroke 3eHealthSource.com Launches Online Shopping Site Dedicated to Over-the Counter Medications Approved for FSA/HSA Claims 2Health Robotics to Unveil TPNstation(TM) at the American Society of Health-System Pharmacists on December 7th 2Health Robotics to Unveil TPNstation(TM) at the American Society of Health-System Pharmacists on December 7th 3Rigel Announces Pricing of Public Offering of 13 000 000 Shares of Common Stock 14119 1Rigel Announces Pricing of Public Offering of 13 000 000 Shares of Common Stock 14119 2Experts Outline Challenges to Translational Research in the United States at a Capitol Hill Briefing Emphasizing the Importance of Bringing Medical I 57486 1Experts Outline Challenges to Translational Research in the United States at a Capitol Hill Briefing Emphasizing the Importance of Bringing Medical I 57486 2Experts Outline Challenges to Translational Research in the United States at a Capitol Hill Briefing Emphasizing the Importance of Bringing Medical I 57486 3Experts Outline Challenges to Translational Research in the United States at a Capitol Hill Briefing Emphasizing the Importance of Bringing Medical I 57486 4Bones May Suffer From Green Tea Consumption 57484 1
...raging Response in CF Patients - Results Validate..., BETHESDA, Md., March 27 The Cystic Fibrosis Fo... in development that targets a,basic defect in CF,...linical trial for patients who carry the G551D mut... Pharmaceuticals Incorporated., Patients who took...
...epligen Corporation,(Nasdaq: RGEN ) announced tod...al trial to evaluate the use of RG1068, synthetic ...eatic duct structures by magnetic resonance,imagin...eline-controlled,single dose study in which approx...I followed by a secretin-enhanced MRI of the pancr...
Other Medicine Technology:Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF 2Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF 3Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 2Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 3Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 4
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
Medicine Products: